Nowadays, PDE5 inhibitors have approved indications for their use in erectile dysfunction and pulmonary hypertension, and have a potential in the treatment of pathological states featuring endothelial dysfunction, including diabetes and the metabolic syndrome, heart failure and Raynaud’s phenomenon [79]. The gene discussed is PDE5A; the disease is erectile dysfunction.